Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) was the target of some unusual options trading activity on Wednesday. Stock traders purchased 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the average volume of 165 put options.

Xenon Pharmaceuticals Stock Down 1.7%

XENE stock opened at $43.05 on Thursday. The firm has a market capitalization of $3.58 billion, a PE ratio of -9.87 and a beta of 0.91. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.99. The stock’s 50 day moving average is $42.37 and its 200-day moving average is $41.15.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period last year, the company posted ($0.84) earnings per share. On average, equities research analysts anticipate that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on XENE shares. JPMorgan Chase & Co. raised their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Stifel Nicolaus set a $66.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Needham & Company LLC lifted their price target on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Finally, Wells Fargo & Company increased their price objective on shares of Xenon Pharmaceuticals from $48.00 to $49.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $55.50.

Insider Buying and Selling

In related news, CEO Ian Mortimer sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer owned 6,000 shares of the company’s stock, valued at $266,580. This trade represents a 86.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 65,205 shares of company stock worth $2,919,762 over the last quarter. Corporate insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in Xenon Pharmaceuticals in the 4th quarter worth about $55,000. Corient Private Wealth LLC purchased a new position in shares of Xenon Pharmaceuticals in the 4th quarter worth approximately $1,125,000. Mackenzie Financial Corp bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $210,000. ADAR1 Capital Management LLC increased its position in shares of Xenon Pharmaceuticals by 7.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock valued at $9,142,000 after acquiring an additional 14,871 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth $964,000. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.